Cargando…

Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue

Most patients with epithelial ovarian cancer eventually die due to recurrence. However, little is known about the microRNA (miRNA) expression pattern and its involvement in recurrent ovarian cancer. We analyzed miRNA expression profiles related to the recurrence of advanced ovarian high-grade serous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nam, Eun Ji, Kim, Sunghoon, Lee, Taek Sang, Kim, Hee Jung, Lee, Jung Yun, Kim, Sang Wun, Kim, Jae Hoon, Kim, Young Tae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342571/ https://www.ncbi.nlm.nih.gov/pubmed/27655640 http://dx.doi.org/10.18632/oncotarget.12045

Ejemplares similares

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
por: Lee, Yong Jae, et al.
Publicado: (2022)

Prognostic value of complete metabolic response on (18)F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2022)

External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
por: Lee, Jung-Yun, et al.
Publicado: (2017)

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience
por: Chung, Young Shin, et al.
Publicado: (2018)

Long Non-coding RNA HOXA11 Antisense Promotes Cell Proliferation and Invasion and Predicts Patient Prognosis in Serous Ovarian Cancer
por: Yim, Ga Won, et al.
Publicado: (2017)

Genetic analysis of ovarian microcystic stromal tumor
por: Lee, Jae Hoon, et al.
Publicado: (2016)

Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2020)

MicroRNA profiling of a CD133(+) spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line
por: Nam, Eun Ji, et al.
Publicado: (2012)

Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2020)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2019)

Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma
por: Kim, Se Ik, et al.
Publicado: (2022)

ATP-Based Chemotherapy Response Assay in Primary or Recurrent Ovarian and Peritoneal Cancer
por: Lee, Maria, et al.
Publicado: (2014)

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Role of diagnostic laparoscopy in deciding primary treatment in advanced-stage ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2022)

Expression Profiles of ID and E2A in Ovarian Cancer and Suppression of Ovarian Cancer by the E2A Isoform E47
por: Lee, Yong-Jae, et al.
Publicado: (2022)

Diagnostic and prognostic role of circulating neutrophil extracellular trap markers and prekallikrein in patients with high-grade serous ovarian cancer
por: Kim, Jisoo G., et al.
Publicado: (2022)

Clinical Significance of Microsatellite Instability in Sporadic Epithelial Ovarian Tumors
por: Yoon, Bo-Sung, et al.
Publicado: (2008)

Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer
por: Kim, Yoo-Na, et al.
Publicado: (2019)

Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer
por: Lee, Yong Jae, et al.
Publicado: (2019)

A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer
por: Li, Lan Ying, et al.
Publicado: (2019)

Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma
por: Choi, Min Chul, et al.
Publicado: (2020)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery
por: Eoh, Kyung Jin, et al.
Publicado: (2016)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Dysregulated expression of homeobox family genes may influence survival outcomes of patients with epithelial ovarian cancer: analysis of data from The Cancer Genome Atlas
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
por: Park, Junsik, et al.
Publicado: (2020)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

USP19 and RPL23 as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma
por: Kang, Haeyoun, et al.
Publicado: (2021)

Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center
por: Lee, Yong Jae, et al.
Publicado: (2018)

Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2023)

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
por: Lee, Yong Jae, et al.
Publicado: (2022)

Dysregulation of X Chromosome Inactivation in High Grade Ovarian Serous Adenocarcinoma
por: Kang, Jun, et al.
Publicado: (2015)

Comparison of single-port laparoscopy and laparotomy in early ovarian cancer surgical staging
por: Cho, Kyu Hee, et al.
Publicado: (2021)

Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer
por: Kim, Yun-Ji, et al.
Publicado: (2018)

Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jbjrn2n0pelcv9gkvaph9b0qkl